Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

BACKGROUND: We address the prognostic and predictive value of KRAS, PIK3CA and BRAF mutations for clinical outcomes in response to active agents in the treatment of metastatic colorectal cancer (mCRC). METHODS: We determined KRAS, BRAF and PIK3CA mutations in tumours from 168 patients treated for mC...

Descripción completa

Detalles Bibliográficos
Autores principales: Souglakos, J, Philips, J, Wang, R, Marwah, S, Silver, M, Tzardi, M, Silver, J, Ogino, S, Hooshmand, S, Kwak, E, Freed, E, Meyerhardt, J A, Saridaki, Z, Georgoulias, V, Finkelstein, D, Fuchs, C S, Kulke, M H, Shivdasani, R A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720232/
https://www.ncbi.nlm.nih.gov/pubmed/19603024
http://dx.doi.org/10.1038/sj.bjc.6605164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720232/
https://www.ncbi.nlm.nih.gov/pubmed/19603024
http://dx.doi.org/10.1038/sj.bjc.6605164

Ejemplares similares